Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M4OC-Prevent: Metformin for Oral Cancer Prevention
NCT02581137Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of liquid metformin (Aspargo Labs) in oral cancer, oral leukoplakia, erythroplakia, sponsored by National Cancer Institute. Started Jun 2016; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
oral canceroral leukoplakiaerythroplakia
Beyond the preview
Go deeper on NCT02581137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581137.